Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Grant
Adjust height of sidebar
KMap
Grant
A Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab (MK-4280) plus pembrolizumab (MK-3475)) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory C
Active
$1.3M Funding
2 People
External
Related Topics
immunotherapy,
cancer treatment,
clinical trial,
pd-(l)1 inhibitors,
combination therapy
People
Abhijeet Kumar
Principal Investigator (PI)
Medicine
﹒Associate Professor, Medicine - (Clinical Scholar Track)
Michele Holland
(CD)
Cancer Center Division
﹒Research Compliance Administrator II
